The rules on generics have changed. They can no longer piggyback on the data from the approved drug. They no have to do some testing of their own to show that the generic is bio equivalent.
While that is not the level of protection that a patent provides, it is still a fairly high barrier to overcome.
Anavex has patents in progress or granted on the production of the 2-73 molecule. Those provide a degree of protection.
News 
Market Data 
Discover 
